CN-122012696-A - Biomarker for preparing diagnosis of pulmonary fibrosis and application thereof

Abstract

The invention discloses a biomarker for diagnosing pulmonary fibrosis and application thereof, belonging to the technical field of biomarkers of clinical medicine. The biomarker for diagnosing pulmonary fibrosis is nerve growth factor NGF, the nerve growth factor NGF can obviously promote differentiation of lung fibroblast MRC5 cells, and the migration capacity and proliferation capacity of the lung fibroblast cells are obviously enhanced along with the increase of the expression of a receptor TrkA. At the same time NGF also aggravates BLM-induced pulmonary fibrosis formation in mice. Thus nerve growth factor NGF has accurate and specific detection and assisted diagnosis as a biomarker in pulmonary fibrosis, in particular Idiopathic Pulmonary Fibrosis (IPF).

Inventors

• LIU DAISHUN
• ZHU HONGLAN
• WANG SHENGPENG
• ZHOU AIMING
• LAN JUNJIE

Assignees

• 贵州省人民医院

Dates

Publication Date

20260512

Application Date

20260212

Claims (7)

1. 1. A biomarker for preparing a diagnostic lung fibrosis is characterized in that the biomarker is nerve growth factor NGF.
2. 2. The method of claim 1, wherein the pulmonary fibrosis is selected from the group consisting of primary pulmonary fibrosis, secondary pulmonary fibrosis, idiopathic pulmonary fibrosis, interstitial pulmonary fibrosis, and interstitial pneumonia.
3. 3. The biomarker for preparing a diagnostic of pulmonary fibrosis according to claim 1, wherein: the lung fibrosis is idiopathic pulmonary fibrosis.
4. 4. The application of the biomarker in preparing a product for detecting or diagnosing the pulmonary fibrosis is characterized in that the biomarker is nerve growth factor NGF, and the product for detecting or diagnosing the pulmonary fibrosis is a detection reagent, and/or a detection kit, and/or a diagnostic reagent and/or a diagnostic kit.
5. 5. The method according to claim 4, wherein the detection or diagnosis of pulmonary fibrosis product is used to detect the expression level of nerve growth factor NGF in a biological sample.
6. 6. The method according to claim 4, wherein the detection or diagnosis of pulmonary fibrosis is a positive correlation between the detection of pulmonary fibrosis and the expression level of NGF.
7. 7. The method according to claim 4, wherein the biological sample is selected from the group consisting of peripheral blood and tissue samples.

Description

Biomarker for preparing diagnosis of pulmonary fibrosis and application thereof Technical Field The invention relates to the technical field of biomarkers in clinical medicine, in particular to a biomarker for diagnosing pulmonary fibrosis and application thereof. Background Idiopathic Pulmonary Fibrosis (IPF) is a chronic and progressive pulmonary disease affecting interstitial tissue, which is characterized by the usual interstitial pneumonia found by high resolution computed tomography or biopsy, but the specific etiology is currently unknown. The incidence of IPF has increased year by year in recent years. Thus, achieving early detection and early treatment of the disease is of great importance for improving survival of patients. There is growing evidence that immune dysfunction plays a key role in the pathogenesis of Idiopathic Pulmonary Fibrosis (IPF), and that the determination of key inflammatory factors and immune cells that have a significant impact on the onset and progression of IPF provides new diagnostic and therapeutic targets for the diagnosis and treatment of this disease, with great benefit. Disclosure of Invention The invention provides a biomarker for diagnosing pulmonary fibrosis and application thereof. In order to achieve the above object, the present invention is achieved by the following technical scheme: It is a first object of the present invention to provide a method for preparing a biomarker for diagnosing pulmonary fibrosis, the biomarker being nerve growth factor NGF. Further, the pulmonary fibrosis comprises one or more of primary pulmonary fibrosis, secondary pulmonary fibrosis, idiopathic pulmonary fibrosis, pulmonary interstitial fibrosis and interstitial pneumonia. Preferably, the pulmonary fibrosis is idiopathic pulmonary fibrosis. A second object of the present invention is to provide the use of a biomarker for the manufacture of a product for detecting or diagnosing pulmonary fibrosis, said biomarker being nerve growth factor NGF, said product for detecting or diagnosing pulmonary fibrosis being a detection reagent, and/or a detection kit, and/or a diagnostic reagent and/or a diagnostic kit. Further, the detection or diagnosis of pulmonary fibrosis products is used to detect the expression level of nerve growth factor NGF in a biological sample. Further, in the detection or diagnosis of pulmonary fibrosis, the detection of pulmonary fibrosis is positively correlated with the expression level of nerve growth factor NGF. Further, the biological sample is selected from the group consisting of peripheral blood, tissue samples. The invention is used for preparing the biomarker for diagnosing pulmonary fibrosis and the application thereof, and has the beneficial effects that: (1) The biomarker is nerve growth factor NGF, the nerve growth factor NGF can obviously enhance the differentiation of human lung fibroblast MRC5 cells, and the induction and differentiation are accompanied with the increase of the expression of a receptor TrkA, so that the migration capacity and proliferation capacity of the lung fibroblast cells are obviously enhanced. Thus nerve growth factor NGF has accurate and specific detection and assisted diagnosis as a biomarker in pulmonary fibrosis, in particular Idiopathic Pulmonary Fibrosis (IPF). (2) The biomarker provided by the invention is detected by peripheral blood, has the advantages of relatively simple and convenient sampling, better stability and suitability for auxiliary diagnosis, can provide a new technical means for early identification and clinical judgment of pulmonary fibrosis, in particular Idiopathic Pulmonary Fibrosis (IPF), and has the advantages of good repeatability, popularization prospect and the like. Drawings In order to more clearly illustrate the embodiments of the invention or the technical solutions of the prior art, the drawings which are used in the description of the embodiments or the prior art will be briefly described, it being obvious that the drawings in the description below are only some embodiments of the invention, and that other drawings can be obtained according to these drawings without inventive faculty for a person skilled in the art. FIG. 1 is a schematic diagram showing the specific expression results of a biomarker NGF of the invention on Idiopathic Pulmonary Fibrosis (IPF), wherein A is a ROC curve for the diagnosis of the expression level of NGF in a normal healthy person and in an IPF patient, 6 cases each, the expression level of NGF is detected by RT-qPCR after peripheral blood RNA is extracted, B is a volcanic chart for the analysis of mRNA molecules differentially expressed between different groups (IPF/Control) of GSE70866 in an IPF dataset, C is a analysis of the expression variability of NGF in a dataset GSE70866, D is a diagnosis of the expression level of NGF in a dataset GSE70866, E is a diagnosis of Kaplan-Meier survival analysis of NGF high-expression groups and low-expression groups in a d